Designed for clinicians, scientists, and all other members of the cancer care and research community, the ASCO-SITC Clinical Immuno-Oncology Symposium focuses on clinical and translational advances in immuno-oncology. Expert faculty will offer new insights on the application of immunotherapy in lung cancer, genitourinary cancers, melanoma and other skin cancers, breast cancer, and gynecologic cancers. Faculty will also discuss the scientific and clinical relevance of immunogenomics, T Cell therapies, cancer vaccines, the microbiome, and promising combination strategies.
Accreditation and Designation Statement
In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
AMA Credit Designation Statement - Physicians
The American Society of Clinical Oncology designates this live activity for a maximum of 19.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ANCC Credit Designation Statement - Nurses
This CE activity is approved for 19.0 ANCC contact hours.
AAPA/NCCPA Credit Designation Statement – PAs
PAs may claim a maximum of 19.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
All non-physician attendees are welcome to submit a request for a Certificate of Participation, which may enable non-physicians to apply their meeting participation toward re-licensure. Please note, however, that all final decisions regarding certificate acceptance will be made by the licensing organization to which the certificate is submitted.
This Symposium is designed for physicians and researchers involved in multidisciplinary clinical cancer care including, but not limited to medical, surgical, and radiation oncologists; pathologists; radiologists; and other translational-oriented laboratory scientists; nurses, pharmacists, advanced practice providers, and other health care professionals involved in clinical cancer care and cancer research in immuno-oncology.
Educational Needs Statement
In this changing environment, there is a recognition that an improved understanding of the mechanisms enabling and limiting immunotherapy in patients with cancer is needed to identify strategies that will inform clinical research and ultimately improve clinical outcomes for patients. Additionally, with the recent publication of a database that logged over two thousand immuno-oncology agents against over three hundred different targets, it has become a much more challenging goal for both clinicians and researchers to keep pace with the changing landscape.
This symposium will seek to address both significant areas: providing a forum to gain insights into the next phases of immuno-oncology research and how the landscape is likely to evolve, as well as an opportunity to gain clarity on how to optimize the care of patients receiving these therapies. Learners will be introduced to novel approaches and investigational uses of immunotherapy for patients with cancer, even as approvals continue to expand in this area. Questions regarding both the prediction of response and the management of resistance will also be a focus for this symposium, as well as techniques to monitor and manage the unique toxicities that are a potential complication for patients being treated with immunotherapy agents. Across each of these areas, it will be clear that collaboration with the entire cancer care team is critical in optimizing the chances for positive patient outcomes.
Upon participation in this activity, attendees will be able to
- Discuss potential approaches to immunotherapeutic management and novel applications of immunotherapy from the preclinical to the clinical setting in a variety of disease states with varying response characteristics, including lung cancer, melanoma and other skin cancers, breast and gynecologic cancers, among other cancer types;
- Evaluate the latest clinical research related to the diagnosis and management of immune-related adverse events, and incorporate new research insights focused on improving patient safety outcomes;
- Investigate the potential applications of novel immunotherapeutic agents, as well as combination therapies and vaccines, to include reviewing best practices and relevant data to navigate implementation and minimize the toxicity risk of CAR-T therapy;
- Evaluate how mechanisms of resistance can complicate therapeutic selection in the clinical and research setting, and assess the impact of novel discoveries on the appropriate referral of patients to clinical trials;
- Review the applications of genomics data and methods to the field of immuno-oncology, specifically related to use of biomarkers and prediction of response, immunotherapy development, and practical implementation of immunogenetics knowledge, among other topics; and
- Collaborate with all members of the oncology care team to provide eligible patients with cancer with effective, individualized treatment with immunotherapeutic agents, as well as supportive care to minimize toxicity and monitoring to prevent adverse events.
Disclaimer and Unlabeled Usage Statement
The information presented is that of the contributing faculty and presenters and does not necessarily represent the views of the Symposium Cosponsors and/or any named company or organization providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty or presenters. Therefore, before presenting any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions, and adverse effects.
|AstraZeneca||Celgene Corporation||Genentech BioOncology™|
|Gilead Sciences, Inc.||Incyte Corporation||Novartis Oncology|
|Pfizer Oncology||Prometheus Laboratories, Inc|